Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396843 | 0.99 | EPHX1 (0.49) | EPHX1HPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL2926865 | 0.87 | HPGD (0.51) | EPHX1HPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL19410867 | 0.87 | HPGD (0.50) | EPHX1HPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL31170374 | 0.86 | HPGD (0.48) | EPHX1HPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL6507349 | 0.86 | EPHX1 (0.52) | EPHX1HPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL4610629 | 0.85 | EPHX1 (0.48) | EPHX1HPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL1310084 | 0.85 | EPHX1 (0.48) | EPHX1HPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL23439148 | 0.84 | EPHX1 (0.50) | EPHX1HPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL31567046 | 0.84 | HPGD (0.41) | EPHX1HPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL1324396 | 0.84 | EPHX1 (0.50) | EPHX1HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478662-B1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO5) LTD (GB) | 2020-09-16 | — | — | EP | disclosed |
| CN-101374811-A | Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparations | SOLVAY PHARM GMBH (DE) | 2009-02-25 | — | — | CN | disclosed |
| EP-1979319-A1 | NOVEL DUAL NK2/NK3-ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESSES FOR THEIR PREPARATIONS | Solvay Pharmaceuticals GmbH (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-7414057-B2 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414057-B2 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2007088181-A1 | NOVEL DUAL NK2/NK3-ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESSES FOR THEIR PREPARATIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-08-09 | — | — | WO | disclosed |
| WO-2005047253-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
| US-20020137664-A1 | Substituted piperidines as melanocortin-4 receptor agonists | MERCK & CO., INC. | 2002-09-26 | — | — | US | disclosed |
| US-6350760-B1 | OBESITY, DIABETES, SEXUAL DYSFUNCTION; | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137664-A1 | Substituted piperidines as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | EPHX1 3467/4885HPGD 2556/4885USP2 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.